TABLE 1.
Baseline characteristics of the study cohort
| Parameters | All Patients | Died from All Reasons | Died from CV | Died from All Infections | Died from Others (Not Infections and Not CV) | Patients Who Survived |
| No. of patients | 37,250 | 6,147 | 1,183 | 812 | 4,152 | 31,103 |
| Age (years), Median (Q1, Q3) | 64 (52, 74) | 72 (63, 79) | 71 (62, 78) | 72 (63, 79) | 73 (63, 79) | 62 (51, 73) |
| BMI | 25.71 ± 6.62 | 24.27 ± 5.48 | 24.74 ± 5.06 | 24.59 ± 5.54 | 24.06 ± 5.58 | 26.72 ± 5.57 |
| Diabetics (%) | 15.57 | 18.50 | 17.95 | 21.43 | 18.08 | 15.00 |
| Gender: male (%) | 58.60 | 59.77 | 62.55 | 57.64 | 59.39 | 58.37 |
| Catheter (%) | 44.68 | 47.37 | 50.04 | 47.04 | 46.68 | 44.14 |
| Vintage (years), Median (Q1, Q3) | 3.04 (0.13, 4.15) | 2.63 (0.11, 3.78) | 2.73 (0.11, 4.00) | 2.51 (0.10, 3.41) | 2.64 (0.11, 3.74) | 3.12 (0.13, 4.24) |
| Serum albumin (g/dl) | 3.85 ± 0.42 | 3.68 ± 0.49 | 3.75 ± 0.45 | 3.62 ± 0.52 | 3.67 ± 0.49 | 3.89 ± 0.41 |
| Serum creatinine ([mg/dl) | 7.74 ± 2.35 | 6.77 ± 2.09 | 6.96 ± 2.07 | 6.74 ± 2.08 | 6.72 ± 2.09 | 7.94 ± 0.36 |
| CRP (mg/dl), Median (Q1, Q3) | 8.73 (1.16, 10.09) | 12.64 (1.83, 16.00) | 11.29 (1.53, 15.07) | 14.76 (2.66, 19.34) | 12.61 (1.82, 15.72) | 7.96 (1.08, 1.24) |
| NLR | 3.22 ± 2.47 | 3.75 ± 3.00 | 3.52 ± 2.05 | 4.00 ± 3.40 | 3.77 ± 3.11 | 3.12 ± 2.34 |
| LDL-C (mmol/l) | ||||||
| All regions | 2.45 ± 0.87 | 2.39 ± 0.88 | 2.46 ± 0.92 | 2.30 ± 0.91 | 2.39 ± 0.87 | 2.47 ± 0.87 |
| Eastern Europe (n = 6,246) | 2.64 ± 1.02 | 2.54 ± 0.97 | 2.57 ± 1.03 | 2.51 ± 1.00 | 2.53 ± 0.95 | 2.66 ± 1.03 |
| Southern Europe (n = 18,358) | 2.27 ± 0.78 | 2.21 ± 0.81 | 2.20 ± 0.83 | 2.18 ± 0.83 | 2.22 ± 0.81 | 2.29 ± 0.77 |
| Western Europe (n = 1,058) | 2.31 ± 0.93 | 2.31 ± 0.93 | 2.20 ± 0.83 | 2.05 ± 1.63 | 2.35 ± 0.92 | 2.31 ± 0.93 |
| West Asia (n = 10,699) | 2.71 ± 0.83 | 2.70 ± 0.87 | 2.84 ± 0.85 | 2.65 ± 1.03 | 2.67 ± 0.85 | 2.71 ± 0.83 |
| United States (n = 888) | 2.03 ± 0.82 | 2.08 ± 0.81 | 1.96 ± 0.87 | 2.15 ± 0.71 | 2.07 ± 0.82 | 2.02 ± 0.82 |
| HDL-C (mmol/l) | ||||||
| All regions | 1.05 ± 0.34 | 1.03 ± 0.34 | 1.01 ± 0.32 | 1.07 ± 0.34 | 1.03 ± 0.34 | 1.06 ± 0.34 |
| Eastern Europe (n = 6,246) | 1.06 ± 0.36 | 1.00 ± 0.39 | 1.06 ± 0.39 | 1.04 ± 0.38 | 0.98 ± 0.38 | 1.07 ± 0.36 |
| Southern Europe (n = 18,358) | 1.14 ± 0.34 | 1.11 ± 0.33 | 1.09 ± 0.34 | 1.14 ± 0.33 | 1.11 ± 0.33 | 1.15 ± 0.34 |
| Western Europe (n = 1,058) | 1.90 ± 0.41 | 1.12 ± 0.35 | 1.14 ± 0.41 | 1.32 ± 0.19 | 1.11 ± 0.34 | 1.20 ± 0.42 |
| West Asia (n = 10,699) | 0.89 ± 0.26 | 0.88 ± 0.27 | 0.87 ± 0.24 | 0.84 ± 0.25 | 0.89 ± 0.27 | 0.90 ± 0.25 |
| United States (n = 888) | 1.09 ± 0.37 | 1.10 ± 0.38 | 1.00 ± 0.31 | 1.06 ± 0.30 | 1.11 ± 0.40 | 1.09 ± 0.36 |
| TG (mmol/l) | ||||||
| All regions | 1.86 ± 1.02 | 1.72 ± 0.95 | 1.80 ± 1.01 | 1.71 ± 0.95 | 1.69 ± 0.93 | 1.89 ± 1.02 |
| Eastern Europe (n = 6,246) | 1.92 ± 1.13 | 1.87 ± 1.10 | 1.81 ± 1.13 | 1.89 ± 0.94 | 1.89 ± 1.11 | 1.93 ± 1.14 |
| Southern Europe (n = 18,358) | 1.74 ± 0.88 | 1.57 ± 0.78 | 1.63 ± 0.82 | 1.59 ± 0.78 | 1.55 ± 0.77 | 1.77 ± 0.90 |
| Western Europe (n = 1,058) | 1.63 ± 0.90 | 1.42 ± 0.68 | 1.50 ± 0.78 | 1.17 ± 0.71 | 1.41 ± 0.66 | 1.65 ± 0.91 |
| West Asia (n = 10,699) | 2.07 ± 1.13 | 1.93 ± 1.09 | 2.06 ± 1.18 | 1.98 ± 1.28 | 1.88 ± 1.04 | 2.10 ± 1.14 |
| United States (n = 888) | 1.84 ± 1.07 | 1.78 ± 1.09 | 1.71 ± 0.75 | 2.04 ± 1.34 | 1.73 ± 1.04 | 1.86 ± 1.07 |
Data are presented as mean ± SD for normal distributed variables, or median for not normal distributed variables (25th and 75th percentile). All the categorical variables were reported at the time of first lipid measurement. Contentious variables were presented as the average value during the study period.